Cynthia H. Seow

Cynthia H. Seow

Auto-generated profile, based on publicly available information

Cynthia H. Seow

Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
NMN. Mitrev
N. Mitrev
NCN. Vande Casteele
N. Vande Casteele
CSC. H. Seow
C. H. Seow
JAJ. M. Andrews
J. M. Andrews
SCS. J. Connor
S. J. Connor
IGIBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group
IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group

2 March 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
CMC. Ma
C. Ma
RFR. N. Fedorak
R. N. Fedorak
GKG. G. Kaplan
G. G. Kaplan
LDL. A. Dieleman
L. A. Dieleman
SDS. M. Devlin
S. M. Devlin
RPR. Panaccione
R. Panaccione
Summary: Background: Ustekinumab is a monoclonal antibody targeting interleukins‐12 and ‐23, with efficacy in Crohn's disease (CD) demonstrated in clinical trials.Aim: To assess the real‐world clinical, endoscopic and radiographic response and remission outcomes achieved with ustekinumab in medically‐refractory CD.Methods: A retrospective multicentre cohort study was performed on CD patients receiving ustekinumab between 2011 and 2016. The primary outcome was achievement of clinical and objective steroid‐free response and remission at 3, 6 and 12 months. Clinical response and remission were defined by reduction in Harvey Bradshaw Index (HBI) of ≥3 points and an HBI ≤4 points respectively. Objective response was defined by improvement in endoscopic or radiographic CD, as assessed by ileocolonoscopy, contrast‐enhanced ultrasound or CT/MR enterography. Objective remission was defined by endoscopic mucosal healing or complete resolution of inflammatory parameters on radiographic assessment.Results: A total of 167 CD patients were treated with ustekinumab. 95.2% (159/167) previously failed anti‐TNF therapy. Median follow‐up was 45.6 weeks (IQR: 24.4–88.9). At 3 months, clinical response was achieved in 38.9% (65/167) and remission in 15.0% (25/167) of patients. At 6 months, clinical response was achieved in 60.3% (91/151) and remission in 25.2% (38/151) of patients. At 12 months, clinical response was achieved in 59.5% (66/111) and remission in 27.9% (31/111) of patients. Endoscopic or radiographic response was demonstrated in 54.5% (67/123) at 6 months and 55.8% (48/86) of patients at 12 months.Conclusions: Ustekinumab is an effective therapeutic option for inducing and maintaining clinical, endoscopic and radiographic response in patients with Crohn's disease failing anti‐TNF therapy.

20 March 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
CSC. H. Seow
C. H. Seow
YLY. Leung
Y. Leung
NCNiels Vande Casteele
Niels Vande Casteele
EAE. Ehteshami Afshar
E. Ehteshami Afshar
DTD. Tanyingoh
D. Tanyingoh
RPR. Panaccione
R. Panaccione

3 June 2015 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
ARAli Rezaie
Ali Rezaie
MKM Ellen Kuenzig
M Ellen Kuenzig
EBEric I Benchimol
Eric I Benchimol
AGAnne Marie Griffiths
Anne Marie Griffiths
AOAnthony R Otley
Anthony R Otley
CSCynthia H Seow
Cynthia H Seow

21 December 2016 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
MKM. Ellen Kuenzig
M. Ellen Kuenzig
SLSang Min Lee
Sang Min Lee
BEBertus Eksteen
Bertus Eksteen
CSCynthia H. Seow
Cynthia H. Seow
CBCheryl Barnabe
Cheryl Barnabe
GKGilaad Kaplan
Gilaad Kaplan
Studies examining the association between smoking and the need for surgery in patients with Crohn’s disease and ulcerative colitis have reached inconsistent conclusions. These studies often do not differentiate between patients undergoing early surgery and patients having surgery later in their disease course. Our study examined the association between smoking status and time to first bowel resection in patients with Crohn’s disease and ulcerative colitis. We searched MEDLINE and EMBASE for studies (n = 12) reporting on the association between smoking status (current, former, and never) and surgery in IBD, and incorporated disease duration in the analysis. Hazard ratios (HR) with 95% confidence intervals (CI) were pooled across studies using random effects models. Current smokers with Crohn’s disease were at increased risk of intestinal resection compared to never smokers (HR 1.27, 95% CI 1.08 to 1.49); however, there was no difference in the need for surgery when comparing former and never smokers (HR 1.11, 95% CI 0.95 to 1.30). In patients with ulcerative colitis, there was no difference in the need for colectomy when comparing current smokers to never smokers (HR 0.98, 95% CI 0.67 to 1.44). Former smokers with ulcerative colitis were at increased risk of colectomy (HR 1.38, 95% CI 1.04 to 1.83) compared to never smokers. Current smokers with Crohn’s disease are at increased risk of surgery, while former smokers with ulcerative colitis have increased risk of colectomy.

31 July 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
PKPaulo Kotze
Paulo Kotze
CMChristopher Ma
Christopher Ma
AAAbdulelah Almutairdi
Abdulelah Almutairdi
AAAhmed Al‐Darmaki
Ahmed Al‐Darmaki
SDShane M. Devlin
Shane M. Devlin
RPRemo Panaccione
Remo Panaccione
Summary: Background: Vedolizumab is an α4β7 integrin antagonist with proven efficacy for inducing and maintaining clinical response and remission in Crohn's disease (CD) and ulcerative colitis (UC).Aim: To evaluate clinical and objective response and remission rates with vedolizumab in a large, real world cohort.Methods: A retrospective cohort study of adult CD and UC patients receiving vedolizumab between 2012 and 2017 was conducted. Primary outcome: clinical or objective response and remission at 3, 6 and 12 months after induction. Clinical remission was defined by complete, steroid‐free absence of symptoms. Objective remission was defined by endoscopic mucosal healing or normalisation of radiographic appearance on contrast‐enhanced ultrasound or CT/MR enterography.Results: The study included 222 vedolizumab patients (122 CD, 100 UC). In CD, clinical remission at 3, 6 and 12 months was achieved in 19.8% (22/111), 22.1% (21/95) and 22.1% (15/68) of patients, respectively. Objective remission occurred in 11.5% (6/52), 21.2% (14/66), and 18.9% (7/37) of patients at 3, 6 and 12 months, respectively. In UC, clinical remission at 3, 6, and 12 months was 51.0% (51/100), 61.8% (55/89) and 61.9% (39/63), respectively. Endoscopic remission occurred in 27.5% (11/40), 41.0% (16/39) and 47.8% (22/46) of patients at 3, 6 and 12 months, respectively. In multivariable analysis, patients with UC as compared to CD, and those with milder disease activity were more likely to achieve objectively defined remission at both 6 and 12 months.Conclusions: Vedolizumab was effective for induction and maintenance of clinical and objective remission, both in Crohn's disease and ulcerative colitis.